Literature DB >> 17968684

Granulomatous slack skin: report of a case with response to electron beam therapy.

Gonca Gokdemir1, Andaç Argon, Damlanur Sakiz, Dilek Argon, Adem Köşlü.   

Abstract

Granulomatous slack skin (GSS) is a rare form of cutaneous T-cell lymphoma, closely related to mycosis fungoides. It is characterized by pendulous skin folds with a predilection for flexural areas. Histology shows an elastolytic granulomatous infiltrate with atypical lymphoid cells. Granulomatous mycosis fungoides is an important histologic differential diagnosis to be considered. We present a 19-year-old man with a gradually enlarging erythematous, and bulky lesions on his body. Histologically, a dense atypical lymphoid cell infiltration with numerous multinucleated giant cells and elastolysis was observed. T-cell receptor gene rearrangement was detected in skin lesions. He was treated with PUVA and interferon alpha, but improvement in skin lesions was not observed. Marked regression of all lesions was achieved by using electron beam therapy. This case report supports that GSS is an indolent variant of mycosis fungoides due to clinical, histological and T-cell gene rearrangement results. However, there is no definitive data about prognosis of the disease. We suggest that further clinical studies are needed to understand this rare condition.

Entities:  

Mesh:

Year:  2007        PMID: 17968684     DOI: 10.1007/s12032-007-9017-z

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  19 in total

1.  Lymphoproliferative nature of granulomatous slack skin: clonal rearrangement of the T-cell receptor beta-gene.

Authors:  S Puig; P Iranzo; J Palou; R Martí; T Estrach; J M Mascaró
Journal:  Arch Dermatol       Date:  1992-04

Review 2.  Clinicopathological spectrum of mycosis fungoides.

Authors:  D V Kazakov; G Burg; W Kempf
Journal:  J Eur Acad Dermatol Venereol       Date:  2004-07       Impact factor: 6.166

Review 3.  EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer.

Authors:  R Willemze; H Kerl; W Sterry; E Berti; L Cerroni; S Chimenti; J L Diaz-Peréz; M L Geerts; M Goos; R Knobler; E Ralfkiaer; M Santucci; N Smith; J Wechsler; W A van Vloten; C J Meijer
Journal:  Blood       Date:  1997-07-01       Impact factor: 22.113

4.  Cutaneous T-cell lymphoma associated with granulomatous slack skin.

Authors:  F Mouly; M Baccard; J M Cayuela; F Janssen; O Verola; B Flageul; P Morel
Journal:  Dermatology       Date:  1996       Impact factor: 5.366

5.  A case of primary cutaneous CD30+ T-cell lymphoproliferative disorder with features of granulomatous slack skin disease.

Authors:  K Wada; C Maesawa; T Satoh; T Akasaka; T Masuda
Journal:  Br J Dermatol       Date:  2002-11       Impact factor: 9.302

6.  Granulomatous mycosis fungoides: report of a case with some histopathologic features of granulomatous slack skin.

Authors:  G Metzler; B Schlagenhauff; S M Kröber; E Kaiserling; G Schaumburg-Lever; G Lischka
Journal:  Am J Dermatopathol       Date:  1999-04       Impact factor: 1.533

7.  Topical nitrogen mustard for the treatment of granulomatous slack skin.

Authors:  Tricia L Hultgren; Dan Jones; Madeleine Duvic
Journal:  Am J Clin Dermatol       Date:  2007       Impact factor: 7.403

Review 8.  The new World Health Organization-European Organization for Research and Treatment of Cancer classification for cutaneous lymphomas: a practical marriage of two giants.

Authors:  D N Slater
Journal:  Br J Dermatol       Date:  2005-11       Impact factor: 9.302

Review 9.  Granulomatous slack skin: treatment with extensive surgery and review of the literature.

Authors:  Magali Clarijs; Françoise Poot; Andoni Laka; Christian Pirard; André Bourlond
Journal:  Dermatology       Date:  2003       Impact factor: 5.366

10.  Granulomatous slack skin disease--disease features and response to pentostatin.

Authors:  Nnenna Osuji; Louise Fearfield; Estella Matutes; Andrew C Wotherspoon; Christopher Bunker; Daniel Catovsky
Journal:  Br J Haematol       Date:  2003-10       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.